Overview

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Status:
Completed
Trial end date:
2018-12-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of TAK-831 versus placebo on upper extremity (arm and hands) motor function and manual dexterity. This study will also evaluate the efficacy of TAK-831 versus placebo on activities of daily living (ADL) and other secondary assessments.
Phase:
Phase 2
Details
Lead Sponsor:
Neurocrine Biosciences
Takeda
Collaborator:
Takeda